ML28485: Phase 2B Single-site, Open-label, Nonrandomized Study Evaluating Efficacy of Oral Vismodegib in Various Histologic Subtypes (Infiltrative/Morpheaform, Nodular and Superficial) of High Risk and/or Locally Advanced Basal Cell Carcinoma

Trial Profile

ML28485: Phase 2B Single-site, Open-label, Nonrandomized Study Evaluating Efficacy of Oral Vismodegib in Various Histologic Subtypes (Infiltrative/Morpheaform, Nodular and Superficial) of High Risk and/or Locally Advanced Basal Cell Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Vismodegib (Primary)
  • Indications Basal cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Jul 2018.
    • 21 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 20 Jan 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top